

Stephan Urban

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7928296/publications.pdf>

Version: 2024-02-01

110
papers

9,877
citations

44069

48
h-index

36028

97
g-index

115
all docs

115
docs citations

115
times ranked

6589
citing authors

#	ARTICLE	IF	CITATIONS
1	Nonlinear partial differential equations and applications: Infection of a human hepatoma cell line by hepatitis B virus. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15655-15660.	7.1	1,075
2	Hepatitis B and D Viruses Exploit Sodium Taurocholate Co-transporting Polypeptide for Species-Specific Entry into Hepatocytes. Gastroenterology, 2014, 146, 1070-1083.e6.	1.3	627
3	Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nature Biotechnology, 2008, 26, 335-341.	17.5	369
4	Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology, 2007, 46, 1759-1768.	7.3	366
5	Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. Journal of Hepatology, 2016, 65, 490-498.	3.7	321
6	Efficient Inhibition of Hepatitis B Virus Infection by Acylated Peptides Derived from the Large Viral Surface Protein. Journal of Virology, 2005, 79, 1613-1622.	3.4	312
7	Strategies to Inhibit Entry of HBV and HDV Into Hepatocytes. Gastroenterology, 2014, 147, 48-64.	1.3	293
8	The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. Journal of Hepatology, 2013, 58, 861-867.	3.7	286
9	Present and future therapies of hepatitis B: From discovery to cure. Hepatology, 2015, 62, 1893-1908.	7.3	269
10	HBV DNA Integration: Molecular Mechanisms and Clinical Implications. Viruses, 2017, 9, 75.	3.3	264
11	Viral and cellular determinants involved in hepadnaviral entry. World Journal of Gastroenterology, 2007, 13, 22.	3.3	245
12	Mapping of the Hepatitis B Virus Attachment Site by Use of Infection-Inhibiting preS1 Lipopeptides and Tupaia Hepatocytes. Gastroenterology, 2005, 129, 234-245.	1.3	225
13	Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor. Journal of Hepatology, 2014, 60, 723-731.	3.7	217
14	Fine Mapping of Pre-S Sequence Requirements for Hepatitis B Virus Large Envelope Protein-Mediated Receptor Interaction. Journal of Virology, 2010, 84, 1989-2000.	3.4	201
15	Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation. Hepatology, 2012, 55, 685-694.	7.3	190
16	First-in-human application of the novel hepatitis B and hepatitis D virus entry inhibitor myrcludex B. Journal of Hepatology, 2016, 65, 483-489.	3.7	187
17	Characterization of a hepatitis B and hepatitis delta virus receptor binding site. Hepatology, 2006, 43, 750-760.	7.3	145
18	Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 580-589.	17.8	129

#	ARTICLE	IF	CITATIONS
19	HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon. <i>Gastroenterology</i> , 2018, 154, 1791-1804.e22.	1.3	128
20	Hepatitis B Virus DNA Integration Occurs Early in the Viral Life Cycle in an <i>In Vitro</i> Infection Model via Sodium Taurocholate Cotransporting Polypeptide-Dependent Uptake of Enveloped Virus Particles. <i>Journal of Virology</i> , 2018, 92, .	3.4	125
21	Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. <i>Gut</i> , 2018, 67, 542-552.	12.1	125
22	Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. <i>Gut</i> , 2021, 70, 1782-1794.	12.1	125
23	NTCP and Beyond: Opening the Door to Unveil Hepatitis B Virus Entry. <i>International Journal of Molecular Sciences</i> , 2014, 15, 2892-2905.	4.1	123
24	Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load. <i>Gut</i> , 2019, 68, 905-915.	12.1	122
25	Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism. <i>Hepatology</i> , 2014, 60, 1483-1493.	7.3	120
26	Impaired uptake of conjugated bile acids and hepatitis b virus pres1 binding in na+ taurocholate cotransporting polypeptide knockout mice. <i>Hepatology</i> , 2015, 62, 207-219.	7.3	116
27	Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. <i>Hepatology</i> , 2013, 58, 31-42.	7.3	113
28	Hepatocyte polarization is essential for the productive entry of the hepatitis B virus. <i>Hepatology</i> , 2012, 55, 373-383.	7.3	108
29	Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome. <i>Oncogene</i> , 1998, 16, 2051-2063.	5.9	105
30	Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts. <i>Hepatology</i> , 2013, 58, 43-53.	7.3	102
31	Hepatitis D virus replication is sensed by MDA5 and induces IFN- β responses in hepatocytes. <i>Journal of Hepatology</i> , 2018, 69, 25-35.	3.7	101
32	Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications. <i>Journal of Hepatology</i> , 2016, 64, S32-S40.	3.7	98
33	The replication cycle of hepatitis B virus. <i>Journal of Hepatology</i> , 2010, 52, 282-284.	3.7	96
34	Carboxypeptidase D (gp180), a Golgi-Resident Protein, Functions in the Attachment and Entry of Avian Hepatitis B Viruses. <i>Journal of Virology</i> , 1998, 72, 8098-8104.	3.4	96
35	Cryo-electron microscopy of hepatitis B virions reveals variability in envelope capsid interactions. <i>EMBO Journal</i> , 2007, 26, 4160-4167.	7.8	95
36	GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of mycludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection. <i>Journal of Hepatology</i> , 2019, 70, e81.	3.7	93

#	ARTICLE	IF	CITATIONS
37	Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. <i>Journal of Hepatology</i> , 2019, 70, 1008-1015.	3.7	90
38	The Pre-S2 Domain of the Hepatitis B Virus Is Dispensable for Infectivity but Serves a Spacer Function for L-Protein-Connected Virus Assembly. <i>Journal of Virology</i> , 2010, 84, 3879-3888.	3.4	78
39	Sodium taurocholate cotransporting polypeptide is the limiting host factor of hepatitis B virus infection in macaque and pig hepatocytes. <i>Hepatology</i> , 2017, 66, 703-716.	7.3	78
40	Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP. <i>Scientific Reports</i> , 2017, 7, 15307.	3.3	72
41	Avian Hepatitis B Virus Infection Is Initiated by the Interaction of a Distinct Pre-S Subdomain with the Cellular Receptor gp180. <i>Journal of Virology</i> , 1998, 72, 8089-8097.	3.4	69
42	Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo. <i>Gut</i> , 2019, 68, 150-157.	12.1	65
43	Evidence that hepatitis B virus replication in mouse cells is limited by the lack of a host cell dependency factor. <i>Journal of Hepatology</i> , 2016, 64, 556-564.	3.7	63
44	Proteoglycans Act as Cellular Hepatitis Delta Virus Attachment Receptors. <i>PLoS ONE</i> , 2013, 8, e58340.	2.5	61
45	Inhibitors of Hepatitis B Virus Attachment and Entry. <i>Intervirology</i> , 2014, 57, 151-157.	2.8	60
46	Stem cell-derived polarized hepatocytes. <i>Nature Communications</i> , 2020, 11, 1677.	12.8	60
47	Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections. <i>Current Opinion in Virology</i> , 2018, 30, 68-79.	5.4	58
48	Restrictive influence of SAMHD1 on Hepatitis B Virus life cycle. <i>Scientific Reports</i> , 2016, 6, 26616.	3.3	56
49	48 weeks of high dose (10 mg) bulevirtide as monotherapy or with peginterferon alfa-2a in patients with chronic HBV/HDV co-infection. <i>Journal of Hepatology</i> , 2020, 73, S52-S53.	3.7	54
50	Cellular Genomic Sites of Hepatitis B Virus DNA Integration. <i>Genes</i> , 2018, 9, 365.	2.4	53
51	T cell receptor grafting allows virological control of hepatitis B virus infection. <i>Journal of Clinical Investigation</i> , 2019, 129, 2932-2945.	8.2	51
52	A Slow Maturation Process Renders Hepatitis B Virus Infectious. <i>Cell Host and Microbe</i> , 2016, 20, 25-35.	11.0	50
53	Inhibition of Duck Hepatitis B Virus Infection by a Myristoylated Pre-S Peptide of the Large Viral Surface Protein. <i>Journal of Virology</i> , 2002, 76, 1986-1990.	3.4	47
54	A new HDV mouse model identifies mitochondrial antiviral signaling protein (MAVS) as a key player in IFN- β induction. <i>Journal of Hepatology</i> , 2017, 67, 669-679.	3.7	47

#	ARTICLE	IF	CITATIONS
55	Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection. <i>EBioMedicine</i> , 2016, 11, 58-67.	6.1	45
56	Entry of hepatitis B and C viruses – recent progress and future impact. <i>Current Opinion in Virology</i> , 2014, 4, 58-65.	5.4	43
57	Envelope Protein-Mediated Down-Regulation of Hepatitis B Virus Receptor in Infected Hepatocytes. <i>Journal of Virology</i> , 2001, 75, 143-150.	3.4	39
58	Hepatitis B Virus Infection of HepaRG Cells, HepaRG-hNTCP Cells, and Primary Human Hepatocytes. <i>Methods in Molecular Biology</i> , 2017, 1540, 15-25.	0.9	39
59	Recapitulation of HDV infection in a fully permissive hepatoma cell line allows efficient drug evaluation. <i>Nature Communications</i> , 2019, 10, 2265.	12.8	39
60	Hepatitis B Virus DNA is a Substrate for the cGAS/STING Pathway but is not Sensed in Infected Hepatocytes. <i>Viruses</i> , 2020, 12, 592.	3.3	39
61	New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies. <i>Journal of Hepatology</i> , 2021, 74, 686-699.	3.7	37
62	Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates. <i>Journal of Hepatology</i> , 2021, 75, 311-323.	3.7	37
63	Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na ⁺ -taurocholate cotransporting polypeptide inhibitor. <i>Analytical and Bioanalytical Chemistry</i> , 2015, 407, 6815-6825.	3.7	35
64	Hepatitis B Virus Infection of a Mouse Hepatic Cell Line Reconstituted with Human Sodium Taurocholate Cotransporting Polypeptide. <i>Journal of Virology</i> , 2016, 90, 4827-4831.	3.4	35
65	T5 Exonuclease Hydrolysis of Hepatitis B Virus Replicative Intermediates Allows Reliable Quantification and Fast Drug Efficacy Testing of Covalently Closed Circular DNA by PCR. <i>Journal of Virology</i> , 2018, 92, .	3.4	35
66	Hepatitis B Virus DNA Integration: In Vitro Models for Investigating Viral Pathogenesis and Persistence. <i>Viruses</i> , 2021, 13, 180.	3.3	34
67	Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread. <i>Journal of Hepatology</i> , 2022, 77, 957-966.	3.7	34
68	De novo synthesis of hepatitis B virus nucleocapsids is dispensable for the maintenance and transcriptional regulation of cccDNA. <i>JHEP Reports</i> , 2021, 3, 100195.	4.9	33
69	Interruption of bile acid uptake by hepatocytes after acetaminophen overdose ameliorates hepatotoxicity. <i>Journal of Hepatology</i> , 2022, 77, 71-83.	3.7	31
70	Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen. <i>Viruses</i> , 2017, 9, 172.	3.3	30
71	Primary Human Hepatocytes Are Susceptible to Infection by Hepatitis Delta Virus Assembled with Envelope Proteins of Woodchuck Hepatitis Virus. <i>Journal of Virology</i> , 2008, 82, 7276-7283.	3.4	28
72	Hepatitis B Virus-Infected HepG2 ^{hNTCP} Cells Serve as a Novel Immunological Tool To Analyze the Antiviral Efficacy of CD8 ⁺ T Cells In Vitro. <i>Journal of Virology</i> , 2015, 89, 7433-7438.	3.4	26

#	ARTICLE	IF	CITATIONS
73	Nuclear PYHIN proteins target the host transcription factor Sp1 thereby restricting HIV-1 in human macrophages and CD4+ T cells. <i>PLoS Pathogens</i> , 2020, 16, e1008752.	4.7	26
74	Spatiotemporal Differences in Presentation of CD8 T Cell Epitopes during Hepatitis B Virus Infection. <i>Journal of Virology</i> , 2019, 93, .	3.4	25
75	The role of hepatitis B virus (HBV) in the development of hepatocellular carcinoma. <i>Seminars in Virology</i> , 1996, 7, 333-347.	3.9	23
76	Generation and characterization of a stable cell line persistently replicating and secreting the human hepatitis delta virus. <i>Scientific Reports</i> , 2019, 9, 10021.	3.3	23
77	Interplay between Hepatitis D Virus and the Interferon Response. <i>Viruses</i> , 2020, 12, 1334.	3.3	23
78	Sequence analysis of integrated hepatitis B virus DNA during HBeAg-seroconversion. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-12.	6.5	22
79	A Soluble Form of the Avian Hepatitis B Virus Receptor. <i>Journal of Biological Chemistry</i> , 1999, 274, 5707-5715.	3.4	21
80	Optimization-by-design of hepatotropic lipid nanoparticles targeting the sodium-taurocholate cotransporting polypeptide. <i>ELife</i> , 2019, 8, .	6.0	20
81	Solid-Phase Synthesis of the Lipopeptide Myr-HBVpreS/2-78, a Hepatitis B Virus Entry Inhibitor. <i>Molecules</i> , 2010, 15, 4773-4783.	3.8	19
82	An anti-viral peptide derived from the preS1 surface protein of hepatitis B virus. <i>BMB Reports</i> , 2008, 41, 640-644.	2.4	19
83	A novel method to precisely quantify hepatitis B virus covalently closed circular (ccc)DNA formation and maintenance. <i>Antiviral Research</i> , 2020, 181, 104865.	4.1	17
84	HDV Seroprevalence in HBsAg-Positive Patients in China Occurs in Hotspots and Is Not Associated with HCV Mono-Infection. <i>Viruses</i> , 2021, 13, 1799.	3.3	17
85	The retinoic acid receptor (RAR) β -specific agonist Am80 (tamibarotene) and other RAR agonists potently inhibit hepatitis B virus transcription from cccDNA. <i>Antiviral Research</i> , 2019, 168, 146-155.	4.1	15
86	Oral administration of a chimeric Hepatitis B Virus S/preS1 antigen produced in lettuce triggers infection neutralizing antibodies in mice. <i>Vaccine</i> , 2018, 36, 5789-5795.	3.8	14
87	Visualization of hepatitis B virus entry “ novel tools and approaches to directly follow virus entry into hepatocytes. <i>FEBS Letters</i> , 2016, 590, 1915-1926.	2.8	12
88	Drug-Drug Interaction Potential of the HBV and HDV Entry Inhibitor Myrcludex B Assessed <i>in vitro</i> . <i>Antiviral Therapy</i> , 2018, 23, 267-275.	1.0	12
89	A Rapid Point-of-Care Test for the Serodiagnosis of Hepatitis Delta Virus Infection. <i>Viruses</i> , 2021, 13, 2371.	3.3	12
90	SAT-202-Endogenous and exogenous IFN responses suppress HDV persistence during proliferation of hepatocytes <i>in vitro</i> . <i>Journal of Hepatology</i> , 2019, 70, e718-e719.	3.7	11

#	ARTICLE	IF	CITATIONS
91	Liver capsule: Entry and entry inhibition of hepatitis B virus and hepatitis delta virus into hepatocytes. <i>Hepatology</i> , 2016, 63, 633-633.	7.3	10
92	Towards curative therapy of chronic viral hepatitis. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, 61-73.	0.5	10
93	Stem cell-derived hepatocytes: A promising novel tool to study hepatitis B virus infection. <i>Journal of Hepatology</i> , 2017, 66, 473-475.	3.7	9
94	The Novel Immunosuppressive Protein Kinase C Inhibitor Sotrastaurin Has No Pro-Viral Effects on the Replication Cycle of Hepatitis B or C Virus. <i>PLoS ONE</i> , 2011, 6, e24142.	2.5	9
95	Interconvertible of a vitamin B6 coenzyme analog derived from pyridoxal 5â€²-phosphate and rhodanine. <i>Tetrahedron</i> , 1996, 52, 14787-14800.	1.9	6
96	Liver Imaging with a Novel Hepatitis B Surface Protein Derived SPECT-Tracer. <i>Molecular Pharmaceutics</i> , 2013, 10, 2230-2236.	4.6	6
97	Editorial overview: Antiviral strategies: Virological and immunological basis for HBV cure. <i>Current Opinion in Virology</i> , 2018, 30, iv-vi.	5.4	6
98	Concentration of Na ⁺ -taurocholate-cotransporting polypeptide expressed after in vitro-transcribed mRNA transfection determines susceptibility of hepatoma cells for hepatitis B virus. <i>Scientific Reports</i> , 2021, 11, 19799.	3.3	6
99	PS-155-HBV entry inhibition after interferon alpha treatment hinders HBV rebound in hepatocytes that became negative for all HBV markers during interferon treatment. <i>Journal of Hepatology</i> , 2019, 70, e98.	3.7	4
100	A sensitive and Specific PCR-based Assay to Quantify Hepatitis B Virus Covalently Closed Circular (ccc) DNA While Preserving Cellular DNA. <i>Bio-protocol</i> , 2021, 11, e3986.	0.4	4
101	Detection of Low Copy Number Integrated Viral DNA Formed by <i>In Vitro</i> Hepatitis B Infection. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	3
102	Quantification of Hepatitis B Virus Covalently Closed Circular DNA in Infected Cell Culture Models by Quantitative PCR. <i>Bio-protocol</i> , 2019, 9, e3202.	0.4	3
103	PS-053-A rapid point-of-care device for the diagnosis of hepatitis delta virus infection. <i>Journal of Hepatology</i> , 2019, 70, e32-e33.	3.7	1
104	Virus-Derived Peptides for Hepatic Enzyme Delivery. <i>Molecular Pharmaceutics</i> , 2021, 18, 2004-2014.	4.6	1
105	Safety and efficacy of up to 76 weeks 10 mg (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis. <i>Journal of Hepatology</i> , 2020, 73, S861-S862.	3.7	0
106	Pre-clinical characterization of an HBsAg-specific monoclonal antibody preventing HBV spreading and reducing HBV, HDV and HBsAg in serum of humanized mice. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.5	0
107	Title is missing!. , 2020, 16, e1008752.		0
108	Title is missing!. , 2020, 16, e1008752.		0

#	ARTICLE	IF	CITATIONS
109	Title is missing!. , 2020, 16, e1008752.		0
110	Title is missing!. , 2020, 16, e1008752.		0